OX1-Selective Therapeutic Compounds With Extended Receptor Residency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds that are potent inhibitors of the orexin-1 (OX1) receptor with selectivity over the orexin-2 (OX2) receptor, exhibiting increased residency time at OX1 receptors, and possessing favorable pharmaceutical properties for the treatment of CNS disorders such as addictive disorders, sleep-wake cycle disorders, and psychiatric conditions.
Innovation Solution
Development of compounds, such as N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)-N-[(2S)-1-{[5-(trifluoromethyl)pyrazin-2-yl]amino}propan-2-yl]pyridine-2-carboxamide, which act as selective OX1 receptor inhibitors, offering prolonged receptor blockade and favorable pharmaceutical properties like solubility, metabolic stability, and brain penetration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dual OX1 and OX2 antagonists are used to treat sleep disorders, then sleep-wake cycle regulation is improved, but selectivity for OX1 receptor is reduced and off-target effects increase
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (formula I) that exhibit differential binding affinity to OX1 versus OX2 receptors. The chemical structure includes specific substituents (R1-R6, X1-X2 configurations) that create localized interactions favoring OX1 selectivity, allowing the compound to discriminate between similar receptor targets based on subtle structural differences in the binding pocket.
Solution Approach 2:
The patent utilizes parameter changes by systematically varying chemical parameters (substituent types, steric configurations, electronic properties) across the compound series to optimize the balance between OX1 affinity and OX2 selectivity. By adjusting parameters such as the pyridine substitution pattern, triazole positioning, and side chain configurations, the compounds achieve enhanced OX1 selectivity while maintaining therapeutic efficacy.
2Duration of action of moving object
If compounds with increased residency time at OX1 receptors are developed, then duration of action is extended, but binding affinity to OX2 receptors may increase
Solution Approach 1:
The patent applies preliminary action by incorporating structural features (such as the specific pyridine-triazole-amino acid sequence) that pre-position the compound for optimized binding to OX1 receptors. The molecular architecture is designed to engage OX1 binding sites in a manner that facilitates prolonged residence time before dissociation, while the same structure maintains discrimination against OX2 receptors through subtle steric and electronic mismatches.
3Reliability
If compounds with favorable pharmaceutical properties are synthesized, then bioavailability and metabolic stability are improved, but synthesis complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the synthesis process into modular steps: preparation of the core pyridine-triazole scaffold, attachment of the amino acid side chain, and introduction of specific substituents. This modular approach allows each segment to be optimized independently for both pharmaceutical properties and synthetic efficiency, reducing overall process complexity while maintaining compound quality.
Data Source
AI summary
The present invention relates to compounds that are antagonists of the orexin-1 receptor. The compounds have the structural formula (I) defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with orexin-1 receptor activity.